insights_auto
Why is CVM down 6.90%?
Dive Deeperchevron_right
CVM:NYSEAMERICAN
CEL-SCI Corp
$1.35
arrow_downward
-6.90%(-0.10) 1D
$1.39
arrow_upward
+2.96% (+0.040)bedtimeAfter hours
Closed: Nov 9, 4:00:00 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CVM...
Open
$1.45
High
$1.53
Low
$1.35
Mkt. cap
23.75M
Avg. vol.
233.49K
Volume
53.93K
52-wk high
$7.80
52-wk low
$0.89
EPS
-$2.68
Beta
0.62
Shares outstanding
17.59M
No. of employees
43
Open
$1.45
High
$1.53
Low
$1.35
Mkt. cap
23.75M
Avg. vol.
233.49K
Volume
53.93K
52-wk high
$7.80
52-wk low
$0.89
EPS
-$2.68
Beta
0.62
Shares outstanding
17.59M
No. of employees
43
News stories
From web sources and news partners
Stocktwits
·
1 hour ago
Dow, S&P 500, Nasdaq Futures Mixed As Traders Weigh AI Rebound, Await Inflation Data: HIMS, TTD, NVDA, MARA In Focus
BigGo Finance
·
5 hours ago
Dow Soars 1,104 Points in Biggest Gain in Seven Months, but Fed Officials Throw Cold Water on the Rally
bloomingbit
·
7 hours ago
Nvidia Falls 4.3% as S&P 500 Rises 2.3% in Rare Divergence Last Seen 17 Years Ago
Bespoke Investment Group
·
14 hours ago
Bespoke | My Research
Profile
Cel-Sci Corporation, is a biotechnology company that tests drugs for the treatment of cancer, autoimmune and infectious diseases through the research and development of immunotherapy products.
Cel-Sci's main product is the drug Multikine, an immunotherapeutic agent designed to fight cancer by stimulating the body's immune system. Multikine is currently in Phase III of Clinical Trials with the Food and Drug Administration. Multikine has also been referred to as Leukocyte Interleukin Injection. Multikine was in Phase II testing of patients with head and neck cancer in the early 2000s, in which it demonstrated tumor-reducing ability. In January 2007, the US cleared the Phase 3 trial and Multikine was designated as an orphan drug by the FDA for neoadjuvant therapy of patients with squamous cell carcinoma of the head and neck. A total of 928 patients were enrolled in the head and neck cancer drug trial at that time. Subsequently, in June 2021, the company announced that the study missed its primary endpoint. Wikipedia
About CEL-SCI Corp
CEO-
Employees43
FoundedMar 1983
HeadquartersVienna, Virginia, United States
SectorHealth Care
IndustryBiotechnology
Websitecel-sci.com